1. Catalog
  2. Gene Modulation in HBV
Gene Modulation in HBV
Gene Modulation in HBV
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $25.00
Patient: $0.00
Associate: $0.00
Student: $0.00
Early Career: $0.00
Industry Rep: $25.00
Credit Offered
0.25 AMA PRA Category 1 Credit
0.25 Participation Credit
  • Description
  • Learning Objectives
  • Faculty and Disclosures
  • Privacy Policy
  • Recommended
Gene modulation has become a promising approach for the future treatment of hepatitis B. During this session, Dr. Wong and Dr. Mak will discuss the emerging approaches to inhibit cccDNA including gene editing (e.g., CRISPR Cas-9, ARCUS) and epigenetic modifiers (e.g., KDM5 demethylase inhibitor, HBx inhibitor) that will target a functional cure and move toward a sterilizing cure, identify the current status of the development of these approaches, as well as the potential risks such as off-target effects and the benefits to these new approaches. The session will be applicable to hepatologists, gastroenterologists, fellows and trainees.

Release Date: 7/10/2025
Expiration Date: 7/10/2027

COPYRIGHT: All faculty in this activity have given their permission for publication ©2025 AASLD.
Upon completion of this activity, a participant should be able to

  • Define the emerging approaches to gene modulation of HBV that target a functional cure
  • Identify the current status of development of these approaches
  • Define the potential risks and benefits of the new approaches

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Grace Lai-Hung Lai-Hung Wong, MD, MBChB(Hons), MD, FRCP(Lond, Edin), FHKCP, FHKAM(Medicine)
Scientific Consultant/Advisor: AstraZeneca, Barinthus Biotherapeutics, Gilead Sciences, GlaxoSmithKline, Janssen and Virion Therapeutics Grant/Research Support: Gilead Speakers Bureau: Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, Janssen,  Roche

Lung Yi (Loey) MAK
Nothing to Disclose

Terry Cheuk-Fung Yip, PhD
Scientific Consultant/Advisor: Gilead
Grant/Research Support: Gilead

Powered By